ERBB2 and non-small cell lung carcinoma: Additionally, trastuzumab deruxtecan, a novel HER2 antibody-drug conjugate, has shown promising therapeutic effects in HER2-mutant NSCLC with an ORR of 61.9% and a mPFS of 14.0 months in a phase II trial (30).